The Technical Analyst
CASI Pharmaceuticals Inc [CASI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
CASI Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.29% $2.51
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 33.64 mill |
| EPS: | -2.02 |
| P/E: | -1.240 |
| Earnings Date: | Apr 24, 2024 |
| SharesOutstanding: | 13.40 mill |
| Avg Daily Volume: | 0.208 mill |
| RATING 2024-04-23 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.240 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.21x |
| Company: PE -1.240 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.11 - 2.91 ( +/- 15.82%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-09-07 | Zukiwski Alexander A | Buy | 3 000 | Employee Stock Option (Right to Buy) |
| 2022-09-06 | Huang James | Buy | 33 300 | Common Stock |
| 2022-08-31 | Huang James | Buy | 400 | Common Stock |
| 2022-08-24 | Huang James | Buy | 39 527 | Common Stock |
| 2022-08-19 | Huang James | Buy | 40 000 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 95 transactions |
| Buy: 27 815 562 | Sell: 9 916 643 |
Forecast:
16:00 - $2.44
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.44
Forecast 2: 16:00 - $2.44
Forecast 3: 16:00 - $2.44
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.51 (3.29% ) |
| Volume | 0.0118 mill |
| Avg. Vol. | 0.208 mill |
| % of Avg. Vol | 5.71 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CASI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CASI
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Latest Press Releases
2024-04-08 17:00:00 - Press Release
Casi Pharmaceuticals Reports Development Relating To Its Disputes With Juventas
Beijing , april 8, 2024 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on form 6-k to disclose material development relating to its dispute with juventas. for details, please visit below link: https://www.sec.gov/archives/edgar/data/1962738/000196273824000014/tmb-20240408x6k.htm about casi pharmaceuticals casi pharmaceuticals, inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in china, the united states, and throughout the world.
2024-03-28 07:00:00 - Press Release
Casi Pharmaceuticals Announces Fourth Quarter And Full-year 2023 Business And Financial Results
Beijing , march 28, 2024 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended december 31, 2023, and provided an update on key highlights for 2023. casi reported fourth quarter 2023 revenue of $6.9 million for evomela®, 33% lower than the same period in 2022.
2024-03-05 07:00:00 - Press Release
Casi Pharmaceuticals Report Positive Interim Phase 1 Data For Bi-1206 In The Treatment Of Relapsed/refractory Indolent Non-hodgkin's Lymphoma In China
Beijing and lund, sweden , march 5, 2024 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and bioinvent international ab ("bioinvent") (nasdaq stockholm: binv), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for bi-1206 in combination with rituximab in patients with relapsed/refractory (r/r) indolent non-hodgkin's lymphoma (inhl) in the ongoing development program in china. bi-1206 is a first-in-class fully human monoclonal antibody (mab) that targets fcΓriib.
2024-02-16 07:00:00 - Press Release
Casi Pharmaceuticals Announces First Dosing Of Folotyn® In China
Beijing , feb. 16, 2024 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced the administration of the first dose of folotyn® (pralatrexate injection) to a patient in china. this remarks a pivotal step in casi's commitment to addressing critical medical needs in peripheral t-cell lymphoma in china market.
2023-11-14 07:00:00 - Press Release
Casi Pharmaceuticals Announces Third Quarter 2023 Business And Financial Updates
Beijing , nov. 14, 2023 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the third quarter ended september 30, 2023. dr. wei-wu he, chairman and ceo of casi pharmaceuticals, stated, "we are delighted to announce that our partner juventas has received approval from the china national medical products administration (nmpa) for inaticabtagene autoleucel (anti-cd 19 car-t cell therapy) for the treatment of b-cell acute lymphoblastic leukemia (r/r b-all) in china.
Latest News
2023-01-06 08:42:00 - Market Watch
Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China
Shares of Casi Pharmaceuticals Inc. CASI, +3.63% were up 10% in premarket trading on Friday after the company said China will allow a Phase 1 clinical trial evaluating a multiple myeloma drug developed by the privately held Cleave Therapeutics. The study is expected to start this year.
2022-11-14 09:47:25 - Zacks Investment Research
CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimates
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 25.49% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-09-09 10:32:46 - Benzinga
ALJ Regional Hldgs (NASDAQ:ALJJ), CASI Pharmaceuticals (NASDAQ:CASI) – $2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed higher by around 193 points on Thursday. Investors, meanwhile, focused on some notable insider trades.
2022-08-29 08:58:47 - Benzinga
CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying
The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades.
2022-08-12 12:28:12 - Seeking Alpha
CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q2 2022 Results - Earnings Call Transcript
CASI Pharmaceuticals, Inc. (NASDAQ:CASI ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET Company Participants Wei Zhang – Vice President Wei-Wu He – Chairman and Chief Executive Officer Alex Zukiwski – Executive Vice President and Chief Medical Officer Larry Zhang – President Rui Zhang – Vice President-Business Development Conference Call Participants Leland Gershell – Oppenheimer Sean Lee – H.C. Wainwright Operator Good day everyone and welcome to the CASI Pharmaceuticals' Second Quarter 2022 Earnings Conference Call.
2022-08-12 09:47:04 - Zacks Investment Research
CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 13.85% and 19.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-08-05 08:38:00 - PRNewsWire
CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022
ROCKVILLE, Md. and BEIJING , Aug. 5, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the financial results for the second quarter of 2022, at 8:00 A.M.
2022-06-02 10:44:24 - InvestorPlace
Why Is CASI Pharmaceuticals (CASI) Stock Up 700% Today?
CASI Pharmaceuticals (CASI) stock rocketed higher in pre-market trading this morning but it's not due to any positive news from the company. The post Why Is CASI Pharmaceuticals (CASI) Stock Up 700% Today?
2022-06-02 06:34:34 - Market Watch
CASI Pharmaceuticals stock falls after reverse split takes effect
Shares of CASI Pharmaceuticals Inc. CASI, +18.01% are actually falling in premarket trading Thursday, as a 1-for-10 reverse stock split took effect. While some quote services may still be showing a big gain for the Maryland-based biopharmaceutical company's stock, closed Wednesday at a pre-split price of 40.63 cents, meaning a 1-for-10 reverse split would adjust the price to $4.063.
2022-05-12 11:32:17 - Seeking Alpha
CASI Pharmaceuticals, Inc.'s (CASI) CEO Wei-Wu He on Q1 2022 Results - Earnings Call Transcript
CASI Pharmaceuticals, Inc. (NASDAQ:CASI ) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Wei-Wu He - Chairman and Chief Executive Officer Wei Zhang - President Larry Zhang - President Alexander Zukiwski - Executive Vice President and Chief Medical Officer James Goldschmidt - Chief Business Development Officer Conference Call Participants Justin Zelin - BTIG Sean Lee - HC Wainwright Trevor Allred - Oppenheimer Operator Good morning everyone and welcome to the CASI Pharmaceuticals First Quarter 2022 Business Update and Financial Results Conference Call. All participants will be in a listen-only mode.